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Cost-Effectiveness of Community-based Human 
Immunodeficiency Virus Self-Testing in Blantyre, Malawi
Hendramoorthy Maheswaran,1,2,3 Aileen Clarke,2 Peter MacPherson,3,4 Felistas Kumwenda,3 David G. Lalloo,3,4 Elizabeth L. Corbett,3,5 and Stavros Petrou2
1Department of Public Health and Policy, University of Liverpool, and 2Division of Health Sciences, University of Warwick Medical School, Coventry, United Kingdom; 3Malawi-Liverpool-Wellcome Trust 
Clinical Research Programme, Blantyre, Malawi; and 4Department of Clinical Sciences, Liverpool School of Tropical Medicine, and 5London School of Hygiene and Tropical Medicine, United Kingdom
Background. Human immunodeficiency virus self-testing (HIVST) is effective, with scale-up underway in sub-Saharan Africa. 
We assessed cost-effectiveness of adding HIVST to existing facility-based HIV testing and counseling (HTC) services. Both 2010 
(initiate at CD4 <350 cells/μL) and 2015 (initiate all) World Health Organization (WHO) guidelines for antiretroviral treatment 
(ART) were considered.
Methods. A microsimulation model was developed to evaluate cost-effectiveness, from both health provider and societal per-
spectives, of an HIVST service implemented in a cluster-randomized trial (CRT; ISRCTN02004005) in Malawi. Costs and health 
outcomes were evaluated over a 20-year time horizon, using a discount rate of 3%. Probabilistic sensitivity analysis was conducted 
to account for parameter uncertainty.
Results. From the health provider perspective and 20-year time horizon, facility HTC using 2010 WHO ART guidelines was the least 
costly ($294.71 per person; 95% credible interval [CrI], 270.79–318.45) and least effective (11.64 quality-adjusted life-years [QALYs] per 
person; 95% CrI, 11.43–11.86) strategy. Compared with this strategy, the incremental cost-effectiveness ratio (ICER) for facility HTC 
using 2015 WHO ART guidelines was $226.85 (95% CrI, 198.79–284.35) per QALY gained. The strategy of facility HTC plus HIVST, 
using 2010 WHO ART guidelines, was extendedly dominated. The ICER for facility HTC plus HIVST, using 2015 WHO ART guidelines, 
was $253.90 (95% CrI, 201.71–342.02) per QALY gained compared with facility HTC and using 2015 WHO ART guidelines.
Conclusions. HIVST may be cost-effective in a Malawian population with high HIV prevalence. HIVST is suited to an early 
HIV diagnosis and treatment strategy.
Keywords. HIV; HIV self-testing; ART; cost-effectiveness; cost-utility.
 
More than half of all people living with human immunodeficiency 
virus (PLHIV), new HIV infections, and HIV-related deaths are in 
eastern and southern Africa [1]. Despite intensive efforts to meet 
90-90-90 Joint United Nations Programme on HIV/AIDS testing, 
treatment, and retention goals, nearly half of PLHIV remain una-
ware of their HIV status [2]. HIV testing and counselling (HTC) 
in health facilities is essential but remains underutilized [3]. 
Community-based HIV testing strategies have greater reach, but 
delivery of these services remains costly and difficult to sustain 
and can fail to offer satisfactory levels of privacy [4].
HIV self-testing (HIVST) resolves many of these issues by 
enabling individuals to perform and interpret their own HIV 
test result in private [2] and can be delivered to communities 
safely and at low cost by trained volunteers [5, 6]. HIVST has 
achieved high population HTC uptake, especially among men, 
and good rates of linkage into HIV treatment [5]. However, no 
formal economic evaluation has been undertaken to inform 
regional policy makers whether scaling up of self-testing offers 
efficient use of scarce resources.
Recently, a pragmatic cluster-randomized trial (CRT) was 
undertaken to investigate the impact of offering popula-
tion-wide HIVST through community volunteers in Blantyre, 
Malawi (ISRCTN02004005) [5]. In this study, we undertook 
a cost-effectiveness analysis of this community-based HIVST 
intervention. We sought to use clinical effectiveness and eco-
nomic data collected from participants of this trial [5, 7, 8], as 
well as data from secondary sources, and extrapolate the find-
ings to the population level and over longer time horizons than 
observed in the trial. In addition, we explored the effects of 
changes in World Health Organization (WHO) and Malawian 
antiretroviral treatment (ART) initiation guidelines, which 
occurred after completion of the trial [9].
METHODS
Analytic Overview
We developed a microsimulation model to explore the impact of 
implementing HIVST in communities with high HIV prevalence 
and available facility-based HTC. The model simulates health 
provider and societal costs, health consequences of acquiring 
HIV infection, HIV disease progression, and initiation of ART. 
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Simulating these costs and health consequences at the individ-
ual level has the advantage that parameters (eg, likelihood of 
accessing HIV testing) can reflect individual-level characteris-
tics (eg, age, sex). The model drew heavily on evidence from 
the CRT [5].
Human Immunodeficiency Virus Testing and Treatment Strategies
During the CRT (February 2012 to August 2014), Malawi used 
the 2010 WHO ART guidelines, with ART initiated if the pa-
tient had a CD4 count <350 cells/mm3, was WHO stage 3 or 
4, or was pregnant or breastfeeding [10]. Since August 2016, 
Malawi has used the 2015 WHO ART guidelines with ART 
offered to all HIV-positive individuals [9]. We therefore eval-
uated 4 strategies. The base case was defined as availability of 
facility HTC, using 2010 ART guidelines. We compared this 
strategy to availability of facility HTC plus HIVST, using 2010 
ART guidelines; availability of facility HTC, using 2015 ART 
guidelines; and availability of facility HTC plus HIVST, using 
2015 ART guidelines. We did not consider the potential impact 
of other HIV prevention interventions.
Decision-Analytic Model
Decision-analytic modeling used TreeAge Pro 2017 (TreeAge 
Software, Williamstown, Massachusetts). Figure 1 provides an 
overview of the model structure, which contained the following 
4 health states: HIV negative, HIV positive and not on ART, 
HIV-associated comorbidities, and HIV positive and on ART. 
Every month, individuals transitioned through these health 
states. The model records and, in some cases, updates cer-
tain characteristics including sex, age, HIV status, CD4 count, 
WHO clinical stage, ART status, and months of ART received. 
These characteristics were used to estimate uptake of HIV test-
ing, HIV incidence and prevalence, eligibility for ART initi-
ation, risk of mortality, risk of HIV-associated comorbidities, 
and retention on ART.
Characteristics of Individuals
Baseline population characteristics were estimated from the 
trial post-intervention survey in control clusters, showing 58% 
of participants were female; mean age was 30 years; HIV preva-
lence ranged from 2.3% in males aged 16–19 years to 28.6% in 
females aged 40–49 years; 2.1% were HIV positive with a CD4 
count ≤50 cells/μL and 36.6% were HIV positive with a CD4 
count >500 cells/μL (Table 1).
Human Immunodeficiency Virus (HIV) Testing and Linkage Into HIV Care
Trial data were used to derive probabilities for accessing each 
testing modality by sex and age [5]. Individuals who tested 
HIV negative did not retest for 1 year. In the trial, the HIVST 
service was provided independently of existing facility-based 
HTC. Therefore, we assumed mutually exclusive probabilities 
for accessing HIV testing modalities. Those who tested HIV 
positive through HIVST incurred an additional cost for facili-
ty-based confirmatory HIV testing. A cohort study conducted 
before introduction of HIVST provided estimates of linkage into 
HIV treatment after facility HTC [11]. Linkage into HIV treat-
ment after HIVST was based on trial findings [5]. For strategies 
that included 2010 WHO ART guidelines, data from the litera-
ture were used to model the likelihood of those not eligible for 
ART returning for repeat assessment for ART initiation [12–17].
Figure 1. Overview of the microsimulation model. Abbreviations: ART, antiretroviral treatment; HIV, human immunodeficiency virus; WHO, World Health Organization.
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Transition Probabilities
Death occurred from HIV-related [18, 19] and unrelated 
causes, with Malawian-specific age and sex mortality rates 
used to model HIV-unrelated mortality [20]. HIV-negative 
individuals were at risk of acquiring HIV infection. As the 
model did not allow for interaction between individuals mod-
eled [21], we assumed HIV incidence varied by age and sex 
but was otherwise constant and used estimates from a South 
African study with ART coverage comparable to that in 
Malawi [22].
For HIV-positive individuals, a CD4 count was assigned on 
entry into the model or when infected with HIV. HIV-positive 
individuals’ CD4 counts decreased when not receiving ART 
and increased when receiving ART [23], with rates of change 
estimated from previous studies [16, 19, 24–27]. Modeled CD4 
counts determined individual eligibility to start ART and likeli-
hood of HIV-associated comorbidity or death. The model sim-
ulated progression to WHO clinical stages 3 or 4 [18] to account 
for ART eligibility under 2010 WHO guidelines.
The model was parameterized to account for time-varying 
rates of ART discontinuation [28]. If treatment was discontin-
ued, individuals returned to the “HIV-positive not on ART” 
health state. The model did not account for ART failure or HIV 
viral load monitoring, as this was not offered at the time of the 
trial. ART failure may require switching to more expensive sec-
ond-line ART regimens; however, this remains uncommon in 
the region [29].
For HIV-associated comorbidities, we only considered the 
costs and impact on health-related quality of life (HRQoL) 
arising from hospitalization [30]. For HIV-positive individuals 
not on ART, we multiplied the risk of experiencing these HIV-
associated comorbidities [18, 27] by the risk of hospitalization 
[18]. For HIV-positive individuals on ART, we additionally 
multiplied these risks by the relative reduction in hospitaliza-
tion attributable to ART [31]. We assumed that HIV-positive 
individuals on ART who were hospitalized continued to receive 
ART. We assumed individuals who experienced these comor-
bidities would undergo HIV testing with a similar likelihood 
of linking into HIV treatment as after facility HTC. Additional 
information about the modeling approach (Supplementary 
material Appendix A), model parameter synthesis processes 
(Supplementary material Appendix B), and model external val-
idation procedures (Supplementary material Appendix C) are 
provided.
Costs
The direct health provider and societal costs of facility HTC, 
HIVST, assessment for ART eligibility, and ART were all derived 
from primary costing studies that recruited participants from the 
CRT [7, 8]. The costs associated with different HIV-associated 
comorbidities were derived from primary costing of adult med-
ical admissions to the main public hospital in Blantyre [30]. 
Costs were adjusted to reflect the 1-month cycle length used in 
the model. Societal costs incorporated estimates of direct health 
Table 1. Overview of Base-case Model Parameters
Parameter Data Source
Individual characteristics
Age and sex demographics
HIV prevalence
CD4 counts in HIV positive
58% female; mean age 30 years
2.3%–28.6% (age and sex dependent)
36.6% CD4 count >500 cells/μL
23.4% CD4 count 351–500 cells/μL
22.8% CD4 count 201–350 cells/μL
15.2% CD4 count 51–200 cells/μL
2.1% CD4 count ≤50 cells/μL
Unpublished trial data (post intervention 
survey)
HIV testing and linkage into HIV care
Annual uptake of facility HTC
Annual uptake of HIVST
Linkage after facility HTC
Linkage after HIVST
14.7%–53.0% (age and sex dependent)
40.8%–99.9% (age and sex dependent)
50.7% (95% CI, 44.9–56.6)
41.7% (95% CI, 38.8–44.4)
Unpublished trial data
[5]
[11]
[5]
HIV incidence and mortality
HIV incidence
Non-HIV mortality
HIV mortality, not on ART
HIV mortality, on ART
0.66–6.49 per 100 person-years (age and sex dependent)
Malawi life tables (age and sex dependent)
0.6–69.5 per 100 person-years (CD4 count dependent)
1.4–14.0 per 100 person-years (CD4 count dependent)
[22]
[20]
[18]
[19]
Mean change in CD4 count
Not on ART
On ART
Decreases 4.0–5.7 cells/month (CD4 count dependent)
Increases 1.3 cells/week (95% CI, 1.1–1.5)
[16, 25–27]
[19]
HIV treatment outcomes
Pre-ART returning for ART assessment 
in 6 months
Retention on ART
57.1% (95% CI, 56.0, 58.0)
0–6 months: 86.1% (95% CI, 84.6, 87.4)
7–12 months: 80.2% (95% CI, 78.0, 82.4)
13–24 months: 76.1% (95% CI, 72.4, 79.7)
>24 months: 72.3% (95% CI, 67.4, 76.9)
[12–17]
[28]
HIV-associated illnesses CD4 count dependent [18, 27]
Abbreviations: ART, antiretroviral treatment; CI, confidence interval; HIV, human immunodeficiency virus; HIVST, human immunodeficiency virus self-testing; HTC, human immunodeficiency 
virus testing and counselling. 
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provider costs, direct nonmedical costs, and indirect costs. 
Table 2 shows the cost parameters in 2014 US dollars.
Health-related Quality of Life
The primary health outcome was quality-adjusted life-years 
(QALYs), estimated by multiplying health utility scores assigned 
to the different health states in the model by the time spent in 
each health state and summing across health states [32]. Utility 
scores varied by HIV status. For HIV-positive individuals, 
utility scores decreased as CD4 count decreased and following 
HIV-associated comorbidity [33, 34]. Utility scores for all health 
states were derived from primary economic studies in Blantyre 
that recruited participants from the CRT [7, 8] or from adult 
medical admissions [30]. In these studies the Chichewa version 
of the EuroQoL EQ-5D-3L [35] was used to assess participants’ 
HRQoL. The EQ-5D utility scores for the health states were 
derived using the Zimbabwean [36] EQ-5D tariff set (Table 3).
Cost-Effectiveness Analysis
The model was used to project the costs and QALYs for each 
testing/ART strategy. A time horizon of 20 years rather than the 
standard lifetime horizon [32] was used, given likely changes in 
HIV incidence and testing and treatment strategies over time. 
Scenario analyses included alternative time horizons of 10 and 
40 years.
Probabilistic sensitivity analysis was used to address param-
eter uncertainty. The beta distribution was fitted to transition 
probabilities and health state utilities and to the gamma dis-
tribution for costs [37]. For each strategy, we ran 5000 model 
runs, randomly selecting a value for each parameter from its 
distribution. For each model run, we estimated total costs and 
QALYs for a sample of 5000 individuals.
We report mean discounted costs and QALYs per person 
across these simulations for each testing/ART strategy. We esti-
mated the mean incremental cost and incremental QALYs by 
comparing the least-costly and least-effective strategy to the 
next least-costly and least-effective strategy. The incremental 
cost-effectiveness ratio (ICER) for respective comparators was 
calculated by dividing incremental costs by incremental QALYs 
gained. We excluded strategies that were dominated, that is, less 
effective and more costly, or extendedly dominated, where the 
ICER for the strategy is higher than a more effective strategy. 
All results are presented with 95% credible intervals (CrIs). This 
interval represents the 2.5th and 97.5th percentiles from the 
distribution of results from all simulations. Separate analyses 
were undertaken from health provider and societal perspec-
tives [32]. Costs are represented in 2014 US and international 
dollars, and a discount rate of 3% was applied to both costs and 
health effects.
We compared estimated ICERs against increasing cost-effect-
iveness thresholds as follows: $0/QALY, $250/QALY, $500/
QALY, and $750/QALY. For each testing/ART strategy, we pres-
ent the probability of cost effectiveness at these thresholds. This 
probability represents the proportion of all simulations where 
the estimated ICER was below the specified cost-effectiveness 
threshold [32]. Because we compared multiple strategies and 
because decision makers may have different cost-effectiveness 
thresholds, we also present cost-effectiveness acceptability fron-
tiers (CEAFs) [38] to show which strategy is optimal at increas-
ing cost-effectiveness thresholds. We undertook a series of 
Table 2. Health Provider and Societal Costs for Model 
Cost Parameter
2014 US Dollars
Distribution
Health Provider Costs Societal Costs
Base Case Low High Base Case Low High
Facility-based HTC episode 8.90 7.53 10.57 10.68 9.91 11.45
HIV self-testing episode 8.78 7.78 10.46 8.85 7.97 9.72
Assessment for ART eligibility for all clients 22.27 21.32 23.21 25.46 24.14 26.79
Annual cost of ART for facility HTC clients 168.65 164.69 172.62 181.91 175.38 188.45
Annual cost of ART for facility HIVST clients 164.66 156.41 172.90 179.38 164.29 194.46 Gamma
Cost of hospital admission for severe HIV-associated illness
 Acute diarrhea 300.97 134.37 467.56 481.56 190.30 772.82
 Chronic diarrhea 233.06 93.84 372.28 372.28 114.42 407.39
 Esophageal candidiasis 153.08 69.92 236.24 236.24 65.30 292.59
 Invasive bacterial diseases 223.45 199.68 247.21 247.21 229.39 291.01
 Pulmonary tuberculosis 437.68 339.02 536.33 536.33 441.79 716.81
 Extrapulmonary tuberculosis 494.68 394.83 594.53 594.53 526.86 1014.00
 Malaria 199.63 106.55 292.72 292.72 69.06 647.84
 Malignancy (Kaposi’s sarcoma/Lymphoma) 242.92 195.53 290.31 290.31 244.64 389.41
 Pneumocystis Jivorecii pneumonia 325.56 268.15 382.97 382.97 294.62 495.67
 Cryptococcal meningitis 846.24 651.05 1041.44 1041.44 760.87 1194.62
Abbreviations: ART, antiretroviral treatment; HIV, human immunodeficiency virus; HIVST, human immunodeficiency virus self-testing; HTC, human immunodeficiency virus testing and 
counselling. 
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deterministic sensitivity analyses, using the point estimate for 
all parameters except the one being explored, to evaluate the 
impact on the ICER. We estimated the ICERs across the plaus-
ible ranges for the parameter of interest and present findings in 
a tornado plot.
RESULTS
Health Provider Costs
Over a 20-year time horizon and health provider perspective, 
availability of facility HTC and using 2010 WHO ART guide-
lines was the least costly strategy ($294.71 per person; 95% CrI, 
270.79–318.45; Table 4). The next least costly strategy was fa-
cility HTC and using 2015 WHO ART guidelines ($336.13 per 
person; 95% CrI, 313.35–358.64). The two strategies of facility 
HTC plus HIVST, using either the 2010 or 2015 WHO ART 
guidelines, had higher mean discounted costs of $380.27 (95% 
CrI, 355.08–404.54) and $438.79 (95% CrI, 416.75–461.12) per 
person, respectively.
Societal Costs
Over a 20-year time horizon and societal perspective, facility 
HTC and using 2010 WHO ART guidelines was the least costly 
strategy ($334.70 per person; 95% CrI, 306.45–363.54). The 
next least costly strategy was facility HTC and using 2015 WHO 
ART guidelines ($377.67 per person; 95% CrI, 351.29–405.16). 
The two strategies of facility HTC plus HIVST, using either 
the 2010 or 2015 WHO ART guidelines, had higher mean dis-
counted societal costs of $422.82 (95% CrI, 392.19–452.10) and 
$484.16 (95% CrI, 456.30–512.96) per person, respectively.
Health Outcomes
Over a 20-year time horizon, facility HTC and using 2010 
WHO ART guidelines was the least effective strategy (11.64 
QALYs per person; 95% CrI, 11.43–11.86). The next least ef-
fective strategy was facility HTC and using 2015 WHO ART 
guidelines (11.82 QALYs per person; 95% CrI, 11.62–12.03). 
Facility HTC plus HIVST, using either the 2010 or 2015 WHO 
ART guidelines, was more effective, generating 11.99 (95% CrI, 
11.80–12.18) and 12.23 (95% CrI, 12.06–12.40) QALYs per 
person, respectively.
Cost-Effectiveness Analyses
From the health provider perspective and 20-year time horizon, 
the ICER for facility HTC and using 2015 WHO ART guidelines 
was $226.85 (95% CrI, 198.79–284.35) per QALY gained com-
pared with facility HTC and using 2010 WHO ART guidelines 
(Table 4). The strategy of facility HTC plus HIVST and using 
2010 WHO ART guidelines was extendedly dominated. The 
ICER for facility HTC plus HIVST and using 2015 WHO ART 
guidelines was $253.90 (95% CrI, 201.71–342.02) per QALY 
gained compared with facility HTC and using 2010 WHO ART 
guidelines.
From the societal perspective and 20-year time horizon, the 
ICER for facility HTC plus HIVST and using 2015 WHO ART 
guidelines was $234.69 (95% CrI, 198.76–297.52) per QALY 
gained compared with facility HTC and using 2010 WHO ART 
guidelines. The strategy of facility HTC plus HIVST and using 
2010 WHO ART guidelines was extendedly dominated. The 
ICER for facility HTC plus HIVST and using 2015 WHO ART 
Table 3. EQ-5D Utility Scores for Health States: Zimbabwean and UK Tariff
Utility Parameter
EQ-5D Utility Score
DistributionBase Case Low High
HIV negative 1.000 1.000 1.000 Beta
HIV positive not on ART
 CD4 >200 cells/μL 0.878 0.802 0.954
 CD4 51–200 cells/μL 0.840 0.762 0.917
 CD4 count ≤50 cells/μL 0.654 0.558 0.749
Increase over first year on ART for facility HTC clients 0.129 0.107 0.150
Increase over first year on ART for HIVST clients 0.139 0.087 0.192
Hospital admission for severe HIV associated illness
 Acute diarrhea 0.367 0.143 0.590
 Chronic diarrhea 0.476 0.316 0.636
 Esophageal candidiasis 0.349 0.170 0.529
 Invasive bacterial diseases 0.499 0.457 0.541
 Pulmonary tuberculosis 0.429 0.349 0.509
 Extrapulmonary tuberculosis 0.389 0.296 0.481
 Malaria 0.567 0.412 0.721
 Malignancy (Kaposi’s sarcoma/Lymphoma) 0.420 0.320 0.521
 Pneumocystis Jivorecii pneumonia 0.559 0.398 0.719
 Cryptococcal meningitis 0.478 0.386 0.569
Abbreviations: ART, antiretroviral treatment; HIV, human immunodeficiency virus; HIVST, human immunodeficiency virus self-testing; HTC, human immunodeficiency virus testing and 
counselling. 
Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/cix983/4609427
by guest
on 12 February 2018
6 • CID 2017:XX (XX XXXX) • Maheswaran et al
Ta
bl
e 
4.
 
Co
st
-E
ffe
ct
iv
en
es
s 
Fi
nd
in
gs
 fr
om
 P
ri
m
ar
y 
A
na
ly
si
s 
an
d 
20
-Y
ea
r T
im
e 
H
or
iz
on
 
Pe
rs
pe
ct
iv
e
H
IV
 Te
st
in
g 
S
tr
at
eg
y
A
R
T 
In
iti
at
io
n 
G
ui
de
lin
e
D
is
co
un
te
d 
M
ea
n 
C
os
ts
 a
nd
 Q
A
LY
s 
pe
r 
Pe
rs
on
In
cr
em
en
ta
l  
C
os
t-
E
ffe
ct
iv
en
es
s 
R
at
io
Pr
ob
ab
ili
ty
 C
os
t-
E
ffe
ct
iv
e 
at
  
C
os
t-
E
ffe
ct
iv
en
es
s 
Th
re
sh
ol
db
  
(2
01
4 
U
S
$ 
pe
r 
Q
A
LY
)
20
14
 U
S
$ 
Q
A
LY
s
M
ea
n 
C
os
t
(9
5%
 C
rI
 a
)
In
cr
em
en
ta
l  
C
os
t
(9
5%
 C
rI
 a
)
M
ea
n 
 
E
ffe
ct
iv
en
es
s
(9
5%
 C
rI
 a
)
In
cr
em
en
ta
l  
E
ffe
ct
iv
en
es
s
(9
5%
 C
rI
 a
)
20
14
 U
S
$ 
pe
r 
Q
A
LY
(9
5%
 C
rI
 a
)
0
25
0
50
0
75
0
H
ea
lth
 p
ro
vi
de
r
Fa
ci
lit
y 
H
TC
20
10
 W
H
O
 A
R
T
29
4.
71
 (2
70
.7
9,
 3
18
.4
5)
-
11
.6
4 
(1
1.
43
, 1
1.
86
)
-
-
1.
00
0
0.
12
8
0
0
Fa
ci
lit
y 
H
TC
20
15
 W
H
O
 A
R
T
33
6.
13
 (3
13
.3
5,
 3
58
.6
4)
41
.4
2 
(2
9.
86
, 5
5.
64
)
11
.8
2 
(1
1.
62
, 1
2.
03
)
0.
18
 (0
.1
2,
 0
.2
5)
22
6.
85
 (1
98
.7
9,
 2
84
.3
5)
0
0.
36
2
0.
00
1
0
Fa
ci
lit
y 
H
TC
  
an
d 
H
IV
ST
20
10
 W
H
O
 A
R
T
38
0.
27
 (3
55
.0
8,
 4
04
.5
4)
-
11
.9
9 
(1
1.
80
, 1
2.
18
)
-
E
D
c
0
0.
20
7
0
0
Fa
ci
lit
y 
H
TC
  
an
d 
H
IV
ST
20
15
 W
H
O
 A
R
T
43
8.
79
 (4
16
.7
5,
 4
61
.1
2)
10
2.
66
 (8
5.
45
, 1
20
.0
4)
12
.2
3 
(1
2.
06
, 1
2.
40
)
0.
40
 (0
.2
8,
 0
.5
3)
25
3.
90
 (2
01
.7
1,
 3
42
.0
2)
0
0.
30
3
0.
99
9
1.
00
0
S
oc
ie
ta
l
Fa
ci
lit
y 
H
TC
20
10
 W
H
O
 A
R
T
33
4.
70
 (3
06
.4
5,
 3
63
.5
4)
-
11
.6
4 
(1
1.
43
, 1
1.
86
)
-
-
1.
00
0
0.
17
8
0
0
Fa
ci
lit
y 
H
TC
20
15
 W
H
O
 A
R
T
37
7.
67
 (3
51
.2
9,
 4
05
.1
6)
42
.9
8 
(3
0.
33
, 5
8.
84
)
11
.8
2 
(1
1.
62
, 1
2.
03
)
0.
18
 (0
.1
2,
 0
.2
5)
23
4.
69
 (1
98
.7
6,
 2
97
.5
2)
0
0.
36
8
0.
00
3
0
Fa
ci
lit
y 
H
TC
  
an
d 
H
IV
ST
20
10
 W
H
O
 A
R
T
42
2.
82
 (3
92
.1
9,
 4
52
.1
0)
-
11
.9
9 
(1
1.
80
, 1
2.
18
)
-
E
D
c
0
0.
23
8
0.
00
1
0
Fa
ci
lit
y 
H
TC
  
an
d 
H
IV
ST
20
15
 W
H
O
 A
R
T
48
4.
16
 (4
56
.3
0,
 5
12
.9
6)
10
6.
49
 (8
4.
90
, 1
28
.6
7)
12
.2
3 
(1
2.
06
, 1
2.
40
)
0.
40
 (0
.2
8,
 0
.5
3)
26
2.
68
 (2
03
.7
5,
 3
63
.2
0)
0
0.
21
5
0.
99
6
1.
00
0
20
10
 W
H
O
 A
R
T 
in
iti
at
io
n 
gu
id
el
in
es
: C
D
4 
co
un
t 
<
35
0 
ce
lls
/m
m
3  
or
 W
H
O
 s
ta
ge
 3
 o
r 
4.
 2
01
5 
W
H
O
 A
R
T 
in
iti
at
io
n 
gu
id
el
in
es
: s
ta
rt
 A
R
T 
irr
es
pe
ct
iv
e 
of
 C
D
4 
co
un
t 
or
 W
H
O
 s
ta
ge
.
A
bb
re
vi
at
io
ns
: A
R
T,
 a
nt
ire
tr
ov
ira
l t
re
at
m
en
t;
 C
rI
, 
cr
ed
ib
le
 in
te
rv
al
; 
E
D
, 
ex
te
nd
ed
ly
 d
om
in
at
ed
; 
H
IV
, 
hu
m
an
 im
m
un
od
efi
ci
en
cy
 v
iru
s;
 H
IV
ST
, 
hu
m
an
 im
m
un
od
efi
ci
en
cy
 v
iru
s 
se
lf-
te
st
in
g;
 H
TC
, 
hu
m
an
 im
m
un
od
efi
ci
en
cy
 v
iru
s 
te
st
in
g 
an
d 
co
un
se
lli
ng
; 
Q
A
LY
, 
qu
al
ity
-a
dj
us
te
d 
lif
e-
ye
ar
; W
H
O
, W
or
ld
 H
ea
lth
 O
rg
an
iz
at
io
n.
 
a 9
5%
 C
rI
 r
ep
re
se
nt
s 
th
e 
2.
5t
h 
an
d 
97
.5
th
 p
er
ce
nt
ile
 f
ro
m
 t
he
 d
is
tr
ib
ut
io
n 
of
 r
es
ul
ts
 f
ro
m
 a
ll 
th
e 
si
m
ul
at
io
ns
.
b P
ro
ba
bi
lit
y 
re
pr
es
en
ts
 t
he
 p
ro
po
rt
io
n 
of
 a
ll 
si
m
ul
at
io
ns
 w
he
re
 t
he
 e
st
im
at
ed
 in
cr
em
en
ta
l c
os
t-
ef
fe
ct
iv
en
es
s 
ra
tio
 (I
C
E
R
) w
as
 b
el
ow
 t
he
 s
pe
ci
fie
d 
co
st
-e
ffe
ct
iv
en
es
s 
th
re
sh
ol
d.
 T
ot
al
 m
ay
 n
ot
 a
dd
 u
p 
to
 1
.0
 a
s 
fo
r 
so
m
e 
si
m
ul
at
io
ns
; n
o 
si
ng
le
 s
ce
na
rio
 w
as
 
fo
un
d 
to
 b
e 
th
e 
m
os
t 
co
st
-e
ffe
ct
iv
e 
at
 g
iv
en
 c
os
t-
ef
fe
ct
iv
en
es
s 
th
re
sh
ol
d.
c E
xt
en
de
d 
do
m
in
an
ce
: t
he
 IC
E
R
 fo
r 
th
is
 s
tr
at
eg
y 
w
as
 h
ig
he
r 
th
an
 t
he
 n
ex
t 
m
or
e 
ef
fe
ct
iv
e 
st
ra
te
gy
.
Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/cix983/4609427
by guest
on 12 February 2018
 • CID 2017:XX (XX XXXX) • 7Cost-Effectiveness of HIVST
guidelines was $262.68 (95% CrI, 203.75–363.20) per QALY 
gained compared with facility HTC plus HIVST and using 2010 
WHO ART guidelines. Supplementary material Appendix D 
shows the findings when the costs were estimated in 2014 inter-
national dollars.
Table  4 shows the probability that each strategy is cost ef-
fective at cost-effectiveness thresholds of $0/QALY, $250/QALY, 
$500/QALY, and $750/QALY. Figure 2 shows the CEAF for the 
optimal strategies across increasing cost-effectiveness threshold 
values. Up to a threshold value of approximately $200, the 
strategy of facility HTC and using 2010 WHO ART guidelines 
remained optimal in cost-effectiveness terms. At a cost-effect-
iveness threshold of $250/QALY, the strategy of facility HTC and 
using 2015 WHO ART guidelines was optimal. At threshold val-
ues greater than approximately $270, facility HTC plus HIVST 
and using 2015 WHO ART guidelines was the optimal strategy.
Scenario Analyses
Over both the 10- and 40-year time horizons, the strategy of 
facility HTC plus HIVST and using 2015 WHO ART guidelines 
remained optimal at cost-effectiveness thresholds greater than 
$500 per QALY (Table 5).
Deterministic Sensitivity Analyses
Figure 3 shows a tornado plot from the deterministic sensitivity 
analysis that compares the strategy of facility HTC plus HIVST 
and using 2015 WHO ART guidelines to the strategy of facil-
ity HTC and using 2015 WHO ART guidelines. The uptake of 
facility-based HIV testing and HIVST, cost of HIVST episode, 
and the HIV prevalence and incidence in the population had the 
greatest impact on the ICER. Supplementary material Appendix 
E provides more detail on the findings from the deterministic 
sensitivity analysis.
DISCUSSION
In this study, we undertook an economic evaluation of a com-
munity-based HIV self-testing service in Blantyre, Malawi, and 
estimated cost effectiveness, taking into account recent changes 
in the guidelines for when individuals should start ART. 
Overall, we found that providing community-based HIVST and 
using the 2015 WHO ART guidelines was the optimal strategy 
at cost-effective thresholds greater than $270/QALY. The gross 
domestic product in Malawi is approximately $250 per capita. 
The finding that delivery of HIV testing closer to people’s homes 
is cost effective is not new [39]; however, to our knowledge, this 
is the first evaluation of HIVST strategies to use robust data 
from a large CRT combined with primary economic studies.
Adopting the 2015 WHO ART guidelines or implementing 
HIVST will result in higher healthcare costs. In Malawi, adopt-
ing the 2015 WHO ART guidelines would cost healthcare pro-
viders an additional $41 per capita over the next 20 years and 
Figure 2. Cost-effectiveness acceptability frontier showing optimal strategy at increasing cost-effectiveness threshold values for gain in quality-adjusted life-year. 2010 
World Health Organization (WHO) ART initiation guidelines: CD4 count <350 cells/mm3 or WHO stage 3 or 4. 2015 WHO ART initiation guidelines: start ART irrespective of 
CD4 count or WHO stage. Abbreviations: ART, antiretroviral treatment; HIVST, human immunodeficiency virus self-testing; HTC, human immunodeficiency virus testing and 
counselling; QALY, quality-adjusted life-year; WHO, World Health Organization.
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would equate to a 14% increase in HIV testing and treatment 
expenditures. Adopting both strategies would cost $144 per cap-
ita over the next 20 years and a 49% increase in HIV testing and 
treatment expenditure. However, implementation would have a 
synergistic effect, resulting in the greatest health gains. Uptake 
of HIV testing remains suboptimal in the region [2], with 
HIV-positive individuals with advanced HIV disease still only 
accessing HIV treatment services [40]. Implementing HIVST 
may be necessary to achieve the hoped-for health benefits from 
universal access to ART but needs to be balanced against local 
budgetary constraints and whether investment in other HIV and 
non-HIV interventions offers better value for the money.
We previously estimated the cost per individual tested 
through HIVST to be comparable to facility-based HTC [7]. 
The cost of HIVST kits is currently 8 times that of the rapid fin-
ger-prick test kits used in health facilities. We found the cost of 
an HIVST episode and ART provision to be important drivers 
of cost effectiveness. If the cost of an HIVST episode were lower 
and achievable if the cost of an HIVST kit fell from current esti-
mates of $4 per kit and if the cost of ART provision were lower 
Figure 3. Tornado diagram showing findings from deterministic sensitivity analysis. Abbreviations: ART, antiretroviral treatment; HIV, human immunodeficiency virus; 
HIVST, human immunodeficiency virus self-testing; HTC, human immunodeficiency virus testing and counselling; ICER, incremental cost-effectiveness ratio; KS, Kaposi’s 
sarcoma; MV, multivariate sensitivity analysis; QALY, quality-adjusted life-year; UV, univariate/1-way sensitivity analysis. 
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through lower ART drug costs, implementation of HIVST and 
adoption of the 2015 WHO ART guidelines would be seen as 
more affordable by policy makers in the region.
There are several limitations to our study. First, our analysis 
does not consider the impact of HIV transmission. In compari-
son to the base case, the 3 other strategies examined resulted in 
a net gain in QALYs as well as increased numbers on ART. As 
the number of HIV infections averted depends on ART coverage 
among HIV-positive individuals, considering HIV transmission 
is likely to have led to lower ICER estimates; therefore, our find-
ings represent conservative estimates. Second, we did not con-
sider the impact of individuals failing ART. At the time of the trial 
and of health economic studies, HIV viral load monitoring was 
not routinely available in Malawi and only 3% of HIV-positive 
individuals in the region had switched to second-line ART reg-
imens [29]. However, as all strategies examined result in more 
HIV-positive individuals taking ART, the need for HIV viral load 
monitoring and costlier second-line ART regimens will increase. 
This is likely to lead to less favorable ICERs than those esti-
mated. Finally, we only considered the impact of HIV-associated 
illnesses that required hospitalizations and did not consider other 
illnesses that are managed in the community or at primary health 
clinics. Again, as the costlier strategies result in earlier initiation 
of ART, had we considered these additional health sequelae, the 
ICER estimates would likely have been lower.
Achievement of high coverage of ART is essential to elim-
inating the HIV epidemic in sub-Saharan Africa but will 
require substantial increases in rates of HIV testing. HIVST is 
popular and can have a major impact on population coverage 
of HIV testing, with relatively little input from trained health 
professionals [5, 6]. We found implementation HIVST to be 
potentially cost effective. Notably, our model suggests that the 
transition from restricted ART availability to the 2015 WHO 
ART guidelines of immediate offer of ART irrespective of CD4 
count combines favorably with HIVST. Without effective com-
munity HIV testing programs, the health benefits of universal 
access to ART are limited by the inability to detect early HIV 
efficiently under facility-only testing strategies. HIVST is there-
fore suited to an early HIV diagnosis and treatment strategy.
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